Correspondence: James M. Gold, PhD, Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, PO Box 21247, Baltimore, MD 21228 (jgold@mprc.umaryland.edu).
Submitted for Publication: February 2, 2011; final revision received July 29, 2011; accepted August 4, 2011.
Financial Disclosure: Dr Gold receives royalty payments from the Brief Assessment of Cognition in Schizophrenia and has consulted for Merck, Pfizer, Solvay, GlaxoSmithKline, and AstraZenaca.
Funding/Support: This work was supported by grant R01 MH080066 from the National Institute of Mental Health.
Role of the Sponsors: The funding organization had no role in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; or in the preparation, review, or approval of the manuscript.
Previous Presentation: This study was presented at the 13th International Congress on Schizophrenia Research; April 5, 2011; Colorado Springs, Colorado.
Additional Contributions: Sharon August, MA; Leeka Hubzin, MA; Jacqueline Kiwanuka, MBA; and Dhivya Pahwa, BA, contributed to the study.